TY - JOUR
T1 - SARS-CoV-2 reinfections and subsequent risk of hospital-diagnosed post-acute sequelae in Denmark (2020–2022)
T2 - a nationwide cohort study
AU - Khurana, Mark P.
AU - Brünnich Sloth, Mathilde Marie
AU - Scheidwasser, Neil
AU - Curran-Sebastian, Jacob
AU - Morgenstern, Christian
AU - Banholzer, Nicolas
AU - Thein, David
AU - Mortensen, Laust H.
AU - Rasmussen, Morten
AU - Jokelainen, Pikka
AU - Møller, Frederik Trier
AU - Stegger, Marc
AU - Krause, Tyra G.
AU - Cameron, Ewan
AU - Duchêne, David A.
AU - Katsiferis, Alexandros
AU - Bhatt, Samir
N1 - Publisher Copyright:
© 2026 The Author(s)
PY - 2026/4
Y1 - 2026/4
N2 - Background: Post-acute sequelae of COVID-19 (PASC), or long COVID, are a public health concern. While most recover from SARS-CoV-2 infections within weeks, some experience persistent symptoms. Here, we quantified the association between repeated SARS-CoV-2 infections and the risk of hospital-diagnosed PASC. Methods: We conducted a nationwide register-based cohort study of all adults in Denmark (≥18 years) with at least one SARS-CoV-2 PCR or antigen test between April 1, 2020, and December 31, 2022. Participants were followed from first test until long COVID diagnosis (ICD-10: B948A), death, emigration, three SARS-CoV-2 infections, or end of study. Risk of long COVID diagnosis was estimated at three timepoints after study entry (180 days, 1 year, 2 years) and the outcomes were assessed during the 180 days after each timepoint. Cause-specific Cox models treated death as a competing risk, with number of infections and vaccination status as time-varying covariates. Absolute risks and differences were estimated using G-computation. Analyses were stratified by sex, income, and vaccination status. Secondary analyses assessed fatigue and headache (ICD-10), excluding individuals with prior diagnoses. Findings: Of 4,418,544 individuals, 6942 (0.16%) were diagnosed with long COVID. The absolute risk of a diagnosis increased following reinfection (0.73% [95% CI 0.69–0.77] after one infection vs. 1.16% [1.05–1.30] after two infections at 180 days), but differences were small and decreased over time. Risks following reinfection were similar across sex and income strata. Absolute risk decreased with prior vaccinations. Secondary analyses showed no increased risk of fatigue or headache after primary infection. A small increase in fatigue risk was observed after reinfection at 1 year (RD 0.03% [0.01–0.05]), but not for headache. Interpretation: Reinfection increases long COVID risk; however, the absolute increase after reinfection is smaller than that observed after a primary infection. Vaccination offers substantial protection against long COVID. Funding: Danish National Research Foundation (DNRF).
AB - Background: Post-acute sequelae of COVID-19 (PASC), or long COVID, are a public health concern. While most recover from SARS-CoV-2 infections within weeks, some experience persistent symptoms. Here, we quantified the association between repeated SARS-CoV-2 infections and the risk of hospital-diagnosed PASC. Methods: We conducted a nationwide register-based cohort study of all adults in Denmark (≥18 years) with at least one SARS-CoV-2 PCR or antigen test between April 1, 2020, and December 31, 2022. Participants were followed from first test until long COVID diagnosis (ICD-10: B948A), death, emigration, three SARS-CoV-2 infections, or end of study. Risk of long COVID diagnosis was estimated at three timepoints after study entry (180 days, 1 year, 2 years) and the outcomes were assessed during the 180 days after each timepoint. Cause-specific Cox models treated death as a competing risk, with number of infections and vaccination status as time-varying covariates. Absolute risks and differences were estimated using G-computation. Analyses were stratified by sex, income, and vaccination status. Secondary analyses assessed fatigue and headache (ICD-10), excluding individuals with prior diagnoses. Findings: Of 4,418,544 individuals, 6942 (0.16%) were diagnosed with long COVID. The absolute risk of a diagnosis increased following reinfection (0.73% [95% CI 0.69–0.77] after one infection vs. 1.16% [1.05–1.30] after two infections at 180 days), but differences were small and decreased over time. Risks following reinfection were similar across sex and income strata. Absolute risk decreased with prior vaccinations. Secondary analyses showed no increased risk of fatigue or headache after primary infection. A small increase in fatigue risk was observed after reinfection at 1 year (RD 0.03% [0.01–0.05]), but not for headache. Interpretation: Reinfection increases long COVID risk; however, the absolute increase after reinfection is smaller than that observed after a primary infection. Vaccination offers substantial protection against long COVID. Funding: Danish National Research Foundation (DNRF).
KW - Long COVID
KW - PASC
KW - Post-acute sequelae
KW - Reinfection
KW - SARS-CoV-2
UR - https://www.scopus.com/pages/publications/105028981863
U2 - 10.1016/j.lanepe.2026.101601
DO - 10.1016/j.lanepe.2026.101601
M3 - Journal article
C2 - 41675440
AN - SCOPUS:105028981863
SN - 2666-7762
VL - 63
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
M1 - 101601
ER -